Filing Flows

Filing Flows › 8-K events › Valion Bio

Valion Bio: departure or appointment of directors and officers

Form 8-K filed Nov 2, 2026 · items 5.02, 8.01

FDA decisionsNIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome (“GI-ARS”), after the announcement of positive safety findings

What the filing says

On October 27, 2026, Valion Bio, Inc. (the “Company”) notified Melinda Lackey, the Company’s General Counsel and Senior Vice President of Legal Affairs, of the termination of her employment, effective October 30, 2026. On October 31, 2026, the Company entered into a Separation Agreement and General Release (the “Separa

Read the filing on SEC EDGAR →

What usually followsAcross 39,174 8-Ks reporting Item 5.02 (directors and officers: departures, appointments, pay) in our universe, the stock's median move the next session was −0.1% (typical size ±1.4%, up 48% of the time); over the following 21 sessions, +0.7%. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 5.02 — Departure or appointment of directors and officers. Leadership changes: who leaves, who arrives and on what terms. A sudden CEO or CFO departure without a successor deserves attention.

Valion Bio’s other material 8-Ks

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.